HC Wainwright Forecasts Krystal Biotech Q1 Earnings
HC Wainwright forecasts Krystal Biotech (NASDAQ:KRYS) to report Q1 2026 earnings per share of $1.30, maintaining a "Buy" rating and a $310 price target. This follows Krystal Biotech's Q4 earnings beat with $1.70 EPS and $107.1 million in revenue, driven by strong commercial traction for their drug VYJUVEK. Despite positive analyst sentiment and regulatory wins, the company faces risks including recent insider selling, increased SG&A, and potential delays in European reimbursement for their products.
Krystal Biotech (KRYS): Citigroup Raises Price Target to $371 |
Citigroup has raised its price target for Krystal Biotech (KRYS) to $371 from $336, while maintaining a "Buy" rating. This increase reflects continued optimism from analysts, who anticipate strong performance from the company. Krystal Biotech specializes in developing gene therapies for debilitating dermatological diseases using its proprietary STAR-D platform.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech (NASDAQ:KRYS) reported strong Q4 and full-year 2025 financial results, with net Vyjuvec revenue reaching $107.1 million for the quarter, contributing to a total of over $730 million since launch. The company highlighted significant commercial progress in the US, Europe, and Japan, expanding patient access for Vyjuvec and maintaining high gross margins of 94%. Krystal Biotech also provided updates on its pipeline, including advancements in registrational trials for NK and eye lesions in DEB patients, and announced Fast Track and RMAT designations for KB111 and KB707, respectively.
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
Krystal Biotech (KRYS) reported strong fourth-quarter 2025 earnings per share of $1.70, surpassing estimates, but revenues of $107.1 million missed expectations despite a 17.5% year-over-year increase. The revenue primarily came from sales of Vyjuvek, its gene therapy for dystrophic epidermolysis bullosa, which has seen strong uptake in multiple markets. The company also provided 2026 guidance and detailed updates on its extensive pipeline across respiratory, oncology, dermatology, ophthalmology, and aesthetics.
Krystal Biotech (KRYS) Net Margin Expansion Tests Bullish Long Term Profitability Narratives
Krystal Biotech reported a strong FY 2025 with significant revenue and EPS growth, achieving a 52.6% net profit margin. This margin performance is central to the bullish and bearish arguments about the company's future, with bulls expecting margins to rise further, while bears raise concerns about revenue concentration and growing expenses. The company trades at a P/E premium compared to the industry average, and its valuation is subject to debate, with analyst price targets near current levels but a discounted cash flow suggesting higher value.
Krystal Biotech (KRYS) Net Margin Expansion Tests Bullish Long Term Profitability Narratives
Krystal Biotech (KRYS) reported strong financial results for FY 2025, with Q4 revenue of US$107.1 million and a trailing net profit margin of 52.6%, up from 30.7% a year earlier. This margin expansion is key to bullish investor narratives, though it still falls short of some analysts' projections of 66.3% by 2028. Bearish concerns focus on revenue concentration, rising expenses, and the volatility of net income despite revenue growth, while valuation debates arise from a P/E ratio above the industry average but below its peer group, and a significant difference between the analyst price target and the DCF fair value.
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up Following Strong Earnings
Krystal Biotech (NASDAQ:KRYS) saw its shares gap up following a strong earnings report where it beat EPS and revenue expectations. Analysts subsequently raised price targets, while the company has also seen some insider selling. Institutional investors hold a significant portion of its shares.
Krystal Biotech Surpasses Expectations as VYJUVEK Drives Record 2025 Revenue and International Expansion
Krystal Biotech (NASDAQ: KRYS) reported record financial results for Q4 and full-year 2025, driven by the strong commercial uptake and international expansion of its gene therapy, VYJUVEK. The company achieved substantial increases in revenue and net income, alongside maintaining high gross margins. Krystal Biotech also highlighted significant progress in its clinical pipeline with RMAT designation for KB707 and Fast Track Designation for KB111, positioning itself for continued growth and global market penetration in 2026.
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates
Krystal Biotech (KRYS) saw its stock slip over 2% despite reporting better-than-expected Q4 earnings and revenue. The biotechnology company announced an EPS of $0.05, significantly beating analyst estimates of a $0.94 loss, and revenue of $16.14 million, which also surpassed expectations. This positive financial performance indicates strong growth for the company, even if the market reacted negatively.
Krystal Biotech Q4 Earnings Call Highlights
Krystal Biotech reported strong Q4 2025 results, with VYJUVEK net revenue reaching $107.1 million for the quarter and $389.1 million for the full year, exhibiting a 34% year-over-year increase. The company highlighted ongoing U.S. commercial momentum with over 660 reimbursement approvals and 500 unique prescribers, while anticipating ex-U.S. markets to drive primary revenue growth in 2026. Krystal Biotech also provided updates on its pipeline, including progress on KB407 for cystic fibrosis, protocol changes for KB801 and KB803 to allow at-home dosing, and FDA Fast Track and RMAT designations for KB111 and KB707, respectively.
Krystal Biotech Reports $107.1 Million in 4Q Revenue and FDA Designations for Innovative Gene Therapies
Krystal Biotech announced strong fourth-quarter and full-year 2025 financial results, reporting $107.1 million in VYJUVEK revenue for Q4 and $730.3 million since its U.S. launch. The company also secured RMAT designation for KB707 and Fast Track Designation for KB111 from the FDA, highlighting significant progress in its gene therapy pipeline. With $955.9 million in cash, Krystal Biotech is well-positioned for further development and expansion into international markets, despite ongoing pricing negotiations in Europe.
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Krystal Biotech reported strong financial results for Q4 and full year 2025, with VYJUVEK revenue reaching $107.1 million and $389.1 million respectively. The company also provided significant business updates, including FDA RMAT designation for KB707 in NSCLC, Fast Track Designation for KB111 in HHD, and progress across its diverse pipeline of genetic medicines. Krystal Biotech ended the quarter with $955.9 million in cash and investments, demonstrating a strong financial position.
Krystal Biotech reports Q4 EPS $1.70, consensus $1.61
Krystal Biotech (KRYS) reported Q4 EPS of $1.70, surpassing the consensus estimate of $1.61, and Q4 revenue of $107.1M, exceeding the $105.13M consensus. Chairman and CEO Krish S. Krishnan highlighted significant progress in serving patients with dystrophic epidermolysis bullosa and building global infrastructure, with plans to launch multiple products and treat over 10,000 rare disease patients by 2030, reinforced by promising cystic fibrosis readout.
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q4 Revenue $107.1M, vs. FactSet Est of $105.4M
Krystal Biotech, Inc. (KRYS) reported its Q4 revenue at $107.1 million, surpassing the FactSet estimate of $105.4 million. This announcement was made as part of their latest earnings flash, indicating stronger-than-expected financial performance for the quarter. The company is a commercial-stage biotechnology firm focused on genetic medicines.
Krystal Biotech’s RMAT Win Puts KB707 At Core Of Oncology Story
Krystal Biotech (NasdaqGS:KRYS) received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its immunotherapy candidate KB707, aimed at advanced non-small cell lung cancer. This designation facilitates more frequent FDA interaction and expedited review processes, integrating KB707 into the company's oncology strategy alongside its existing genetic medicines for dermatological diseases. While RMAT does not guarantee approval, it signifies a critical step in expanding Krystal Biotech's platform into significant oncology indications, though it also implies increased R&D spending and clinical risks.
Krystal Biotech in the spotlight with earnings on deck Tuesday
Krystal Biotech (KRYS) is set to report its fourth-quarter earnings on Tuesday, with analysts expecting $1.58 EPS on $106.16 million revenue, driven by the continued commercial success of its gene therapy Vyjuvek. Beyond earnings, investors are keenly watching the company's pipeline, particularly therapies for ocular DEB, neurotrophic keratitis (KB801), and cystic fibrosis (KB407), which could launch by 2028 and justify the company's premium valuation. KB801 is highlighted as a significant catalyst with top-line data expected before year-end 2026, while KB407 shows promising interim Phase 1/2 results, with a registrational trial design to be finalized soon.
TimesSquare Capital Management LLC Grows Holdings in Krystal Biotech, Inc. $KRYS
TimesSquare Capital Management LLC increased its stake in Krystal Biotech, Inc. by 3.8% in the third quarter, bringing its total holdings to 118,514 shares valued at $20.9 million. Analyst ratings show a "Moderate Buy" consensus with an average price target of $277.89, following several upgrades from major brokerages. Despite positive institutional interest and analyst outlooks, insiders Kathryn Romano and Suma Krishnan recently sold a combined 37,500 shares.
Krystal Biotech wins FDA RMAT status for lung cancer therapy
Krystal Biotech has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational therapy, KB408. This therapy is designed to treat alpha-1 antitrypsin deficiency (AATD) associated with lung disease. The RMAT status aims to expedite the development and review of promising regenerative medicine therapies.
Public Sector Pension Investment Board Buys 13,743 Shares of Krystal Biotech, Inc. $KRYS
The Public Sector Pension Investment Board increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 15.9% in Q3, acquiring 13,743 additional shares to reach a total of 100,431 shares valued at approximately $17.73 million. This comes alongside recent insider selling activity from Suma Krishnan and Kathryn Romano. Krystal Biotech, a clinical-stage biotechnology company, currently holds a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $277.89.
Liquidity Mapping Around (KRYS) Price Events
This article provides a detailed liquidity mapping and trading strategy analysis for Krystal Biotech Inc. (NASDAQ: KRYS). It indicates divergent sentiment and potential choppy conditions, highlighting a significant risk-reward short setup. The analysis offers tailored institutional trading strategies for different risk profiles, including position, momentum, and risk-hedging approaches, supported by multi-timeframe signal analysis.
Assessing Krystal Biotech (KRYS) Valuation After KB707 RMAT Designation Boosts Oncology Pipeline Prospects
Krystal Biotech's valuation is under review after its KB707 drug candidate received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for non-small cell lung cancer. The stock has seen significant returns over the last year, leading to questions about its current valuation. While a primary narrative suggests the stock is 1% overvalued at $273.60, another view highlights a P/E ratio of 40.3x, significantly higher than the industry average, indicating potential valuation risk.
Cookson Peirce & Co. Inc. Takes Position in Krystal Biotech, Inc. $KRYS
Cookson Peirce & Co. Inc. recently acquired 5,654 shares of Krystal Biotech, valued at approximately $998,000, bringing institutional ownership in the company to 86.29%. Despite recent insider selling activities, analysts maintain a "Moderate Buy" rating for KRYS with an average price target of $277.89, while the stock currently trades near $276.45. Krystal Biotech specializes in gene therapies for rare dermatological diseases, with its lead candidate targeting dystrophic epidermolysis bullosa.
3 Growth Companies Insiders Are Betting On
Amidst a surging U.S. stock market, this article highlights three growth companies with significant insider ownership, signaling strong internal confidence. Bitdeer Technologies Group is transitioning into AI infrastructure with high forecasted earnings growth, Krystal Biotech focuses on genetic medicines and is trading below fair value, and Hinge Health is expanding its healthcare service delivery with robust revenue growth projections. The analysis suggests these companies offer potential for future growth based on their current strategies and insider stakes.
Krystal Biotech co-founder makes Forbes 250 innovators list
Suma Krishnan, co-founder of Krystal Biotech, has been named to the inaugural Forbes 250 list of America’s Greatest Innovators for her significant contributions to gene therapy and biotechnology. This recognition follows her previous inclusion in the Forbes 50 over 50 list and comes after Krystal Biotech's lung cancer drug, KB707, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The company, initially founded to develop a topical gene therapy for dystrophic epidermolysis bullosa, has grown into a Nasdaq-listed entity with a market cap over US$7 billion, propelled by the success of its FDA-approved drug VYJUVEK.
Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock
Krystal Biotech's CAO, Kathryn Romano, offloaded 12,500 shares of KRYS stock for over $3.4 million on February 9th, reducing her stake by nearly 40%. Despite this insider selling, the stock trades robustly, and analysts maintain a "Moderate Buy" consensus with an average target price exceeding the current trading price. The company is a clinical-stage biotechnology firm focused on gene therapies for rare dermatological diseases.
Krystal Biotech RMAT Win For KB707 And What It Means For Valuation
Krystal Biotech received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707, an inhaled immunotherapy for advanced non-small cell lung cancer, based on early positive clinical evidence. This RMAT status could lead to a faster and more flexible regulatory approval path, attracting investor attention given the company's strong stock performance. While the stock trades below analyst targets and Simply Wall St's fair value estimation, continued positive clinical data for KB707 will be crucial for its future valuation.
Krystal Biotech RMAT Win For KB707 And What It Means For Valuation
Krystal Biotech received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707, an inhaled immunotherapy for advanced non-small cell lung cancer, which could expedite its regulatory pathway. The stock (NasdaqGS:KRYS) is trading around $270.7, reflecting significant multi-year returns, and analysts have a target price of $289.10. While RMAT status adds a potential growth driver, investors should monitor upcoming clinical trial updates and regulatory interactions.
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com
Krystal Biotech's experimental immunotherapy KB707 has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating advanced non-small cell lung cancer, based on early clinical evidence showing significant antitumor activity. This is the second RMAT designation for a Krystal Biotech program and provides benefits like expedited development and potential accelerated approval pathways. The company also reported strong preliminary Q4 and full-year 2025 revenue for its first product, VYJUVEK, and has received positive analyst ratings for its future pipeline.
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech, Inc. announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. markets open. The company will also host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. Investors can access the webcast or a replay on the company's website.
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech, Inc. announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available on the company’s website for at least 30 days.
Krystal Biotech Receives FDA RMAT Designation for KB707
Krystal Biotech's immunotherapy candidate KB707 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for treating non-small cell lung cancer, based on promising early data from the KYANITE-1 study. This designation accelerates the development process by making KB707 eligible for Fast Track and Breakthrough Therapy benefits, enhancing regulatory interactions and speeding up potential approval. KB707 employs an innovative mechanism, delivering cancer-targeting cytokines directly to the tumor microenvironment to combat advanced or metastatic NSCLC.
Krystal Biotech wins FDA RMAT status for cancer drug (KRYS)
Krystal Biotech has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its immunotherapy candidate KB707. This designation applies to treatments for non-small cell lung cancer, recognizing the potential of this gene therapy.
FDA backs KB707 lung cancer immunotherapy with RMAT designation
Krystal Biotech (NASDAQ: KRYS) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational immunotherapy, KB707, for advanced or metastatic non-small cell lung cancer (NSCLC). This designation accelerates development by providing benefits akin to Fast Track and Breakthrough Therapy designations, including intensive FDA interaction and potential for expedited approval. The decision was based on promising early clinical data from the ongoing KYANITE-1 study, which showed significant antitumor activity in heavily pre-treated NSCLC patients.
Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment
Krystal Biotech announced that the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lung cancer treatment. This designation can expedite the development and review of regenerative medicine therapies for serious conditions. The company's stock, KRYS, is listed on Cboe BZX.
Krystal Biotech Announces RMAT Designation Granted by FDA
Krystal Biotech has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KB707, its immunotherapy for advanced or metastatic non-small cell lung cancer (NSCLC). This designation aims to expedite the development of KB707, reflecting the urgent need for new NSCLC therapies and promising early clinical evidence from the KYANITE-1 study. The RMAT status provides benefits similar to Fast Track and Breakthrough Therapy designations, including enhanced FDA guidance and potential for accelerated approval.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
This article analyzes Krystal Biotech, Inc. (KRYS) ahead of its upcoming earnings report, focusing on its Zacks Rank #3 (Hold) and the anticipated 1.57% increase in earnings per share to -$0.54. It highlights the importance of consistency in earnings beats and revenue growth for a potential stock rise, while also noting recent revisions to analyst estimates.
Federated Hermes Inc. Cuts Holdings in Krystal Biotech, Inc. $KRYS
Federated Hermes Inc. reduced its stake in Krystal Biotech (NASDAQ:KRYS) by 43.9% in the third quarter, while several other institutional investors increased their positions. This comes as Krystal Biotech reported strong quarterly earnings, significantly beating analyst estimates, and received multiple analyst upgrades, leading to an overall "Buy" consensus with an average price target of $277.89. The company's stock is largely owned by institutional investors and hedge funds, at 86.29%.
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline
Krystal Biotech (KRYS) is gaining analyst attention due to the potential expansion of its Vyjuvek treatment and its ophthalmic pipeline, including KB803 and KB801. While a popular valuation narrative suggests the stock is slightly overvalued at $282.27 against a $273.60 fair value, a discounted cash flow (DCF) model indicates significant undervaluation with a potential value of $562.69. This discrepancy prompts questions about either analyst caution or the optimism of the cash flow model's assumptions regarding Krystal Biotech's future earnings power and growth.
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision
Several analysts have raised their price targets for Krystal Biotech (KRYS) due to the strong growth of its product Vyjuvek and the potential of its expanding pipeline. Goldman Sachs, Clear Street, and Bank of America all increased their price targets, indicating significant upside potential for the stock. Key drivers include upcoming product launches, promising ophthalmic programs, and investor excitement around the company's neurotrophic keratitis market potential.
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline
Krystal Biotech (KRYS) is gaining analyst attention due to the potential expansion of its Vyjuvek product and its ophthalmic pipeline candidates KB803 and KB801. While a popular narrative suggests the company is slightly overvalued at $282.27 against a fair value of $273.60, a discounted cash flow (DCF) model indicates a much higher intrinsic value of $562.69, suggesting a significant potential undervaluation compared to its current price. This discrepancy prompts investors to consider whether analysts are too cautious or if the cash flow model relies on overly optimistic assumptions, urging a deeper dive into the company's dependency on Vyjuvek and future reimbursement uncertainties.
Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS
Atle Fund Management AB significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 109.3% in the third quarter, purchasing 22,033 additional shares. The firm now holds 42,191 shares valued at approximately $7.45 million, making it their 14th-largest position. This increase follows a strong quarterly earnings report from Krystal Biotech, which exceeded analyst expectations for both EPS and revenue, contributing to a largely bullish outlook from sell-side analysts.
Krystal Biotech stock price target raised to $327 by Goldman Sachs
Goldman Sachs has increased its price target for Krystal Biotech (NASDAQ: KRYS) to $327, maintaining a Buy rating, citing the company's potential to transition into a multi-product firm with three anticipated product launches by 2028. The firm highlighted strong prospects for Krystal's ophthalmic programs (KB803 and KB801) and cystic fibrosis treatment (KB407), alongside the expected geographic expansion of Vyjuvek. Other analysts from H.C. Wainwright, Clear Street, TD Cowen, and BofA Securities have also issued positive ratings and price target adjustments, reflecting a generally optimistic outlook for the company's pipeline and market potential.
Krystal Biotech stock price target raised to $327 by Goldman Sachs
Goldman Sachs has increased its price target for Krystal Biotech (NASDAQ:KRYS) to $327, maintaining a Buy rating, citing the company's potential to become a multi-product firm with three anticipated product launches by 2028. The investment bank highlighted Krystal's promising ophthalmic programs and cystic fibrosis treatment, along with the international expansion of its Vyjuvek treatment. This positive outlook is echoed by other analysts, despite a slight miss in preliminary Q4 2025 revenue estimates.
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp.
EFG Asset Management North America Corp. increased its stake in Krystal Biotech (NASDAQ:KRYS) by 18.4% in the third quarter, acquiring an additional 4,217 shares to hold a total of 27,095 shares valued at approximately $4.78 million. This acquisition comes as Krystal Biotech recently reported strong quarterly earnings, significantly beating analyst expectations with $2.66 EPS and $97.8 million in revenue. Wall Street maintains a positive outlook on the company, with a consensus "Buy" rating and an average price target of $271.75.
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
Krystal Biotech (KRYS) is showing strong upward momentum, characterized by significant price increases over the past 12 weeks and the last four weeks, indicating a sustainable trend for investors. The stock holds a Zacks Rank #1 (Strong Buy) and an Average Broker Recommendation of #1, suggesting robust fundamental strength and positive future performance expectations from analysts. These factors make KRYS a solid choice for "trend" investing, according to Zacks Investment Research.
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction
Recent analyst upgrades and increased earnings estimates for Krystal Biotech (KRYS) have driven market outperformance, with the stock showing strong price action over the last year. While the company is currently trading slightly above the average analyst price target and the narrative fair value suggests it's 3% overvalued, a discounted cash flow model indicates it may be undervalued by 49%. Investors are encouraged to consider the company's reliance on VYJUVEK and early-stage programs, as well as different valuation methodologies, to assess potential buying opportunities.
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction
Krystal Biotech (KRYS) is gaining investor attention due to analyst upgrades, increased earnings estimates, and strong recent stock performance. Despite trading slightly above the average analyst price target, a discounted cash flow (DCF) model suggests the stock may be undervalued by 49%, raising questions about whether the market has fully priced in future growth. The article advises investors to consider both the optimism around its main product, VYJUVEK, and potential risks, alongside its suggested intrinsic discount.
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice
Krystal Biotech, Inc. (KRYS) is highlighted as a strong momentum pick due to its impressive price performance and positive earnings estimate revisions. The article explains how KRYS's Momentum Style Score of B and Zacks Rank #1 (Strong Buy) make it a promising investment, outperforming both its industry and the broader S&P 500. Investors are encouraged to consider KRYS, especially given the rising earnings estimates for both the current and next fiscal year.
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System
The Maryland State Retirement & Pension System reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 50.4% in the third quarter of 2025, selling 3,769 shares and retaining 3,705 worth approximately $654,000. Additionally, insider Suma Krishnan sold 25,000 shares in December for about $5.5 million, though corporate insiders still own a significant portion of the company. Despite these insider and institutional sales, analysts maintain a largely positive outlook with a consensus "Buy" rating and a target price of $271.75.
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS
SG Americas Securities LLC significantly reduced its stake in Krystal Biotech (NASDAQ:KRYS) by 73.7% in the third quarter, now holding 3,318 shares valued at $586,000. Despite this, analysts maintain a "Buy" consensus rating with a target price of $271.75, backed by the company's strong recent earnings, a 53.3% net margin, and trading near its 52-week high. Insiders still own 13.7% of the company, even after a recent 25,000-share sale by insider Suma Krishnan.
